Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective boosted by equities researchers at JPMorgan Chase & Co. from $95.00 to $100.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 16.09% from the company’s previous close.
Several other equities analysts have also weighed in on the company. Wells Fargo & Company raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $78.00 to $100.00 in a research note on Monday. BMO Capital Markets increased their price target on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Cantor Fitzgerald reissued a “neutral” rating and set a $70.00 price objective on shares of Gilead Sciences in a research note on Monday, September 16th. Barclays upped their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $84.83.
View Our Latest Report on Gilead Sciences
Gilead Sciences Trading Up 1.1 %
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. As a group, analysts predict that Gilead Sciences will post 3.78 earnings per share for the current year.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,847 shares of company stock valued at $3,033,340. Insiders own 0.16% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. increased its holdings in shares of Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares during the last quarter. Palisade Asset Management LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth about $29,000. Cedar Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the period. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Financial Connections Group Inc. bought a new position in Gilead Sciences in the 2nd quarter valued at about $34,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Momentum Trades for October With Ample Upside Ahead
- What Are Some of the Best Large-Cap Stocks to Buy?
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- The Significance of Brokerage Rankings in Stock Selection
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.